ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives.

Accumulating evidence has shown that angiopoietin-like-3 (ANGPTL3) plays pivotal roles in biological processes and pathological changes, including kidney diseases. ANGPTL3 expression is overexpressed in patients with proteinuria and glomerular disease. ANGPTL3 up-regulation increases podocyte motility via changes in the expression of nephrin and inducing f-Actin rearrangement, and its suppression mitigates pathological changes in kidney diseases via reducing the apoptotic cells, detached cells, and podocyte loss. Moreover, ANGPTL3 suppression can protect podocytes from injury by inhibiting the ROS/GRP78 signaling pathway in acute kidney injury. ANGPTL3 can indirectly participate in renal pathology by inducing hyperlipidaemia and inflammation. In general, ANGPTL3 inhibition holds promising therapeutic potential for management of kidney diseases, especially those linked to lipid abnormalities. However, it is essential to carefully evaluate potential side effects of ANGPTL inhibitors to guarantee their effective and safe use in clinical settings. The present review summarizes existing knowledge on the role of ANGPTL3 in kidney diseases and ANGPTL3-inhibiting therapies that can be considered as potential treatments for kidney diseases.